Tag Archives: Bispecific T Cell Engager

27Jun/19

Amgen Bispecific Antibody BLINCYTO® (blinatumomab) Significantly Prolongs the Overall Survival Time of Patients with Leukemia

June 27, 2019Bispecific Antibody Clinic, NewsALL, Bispecific T Cell Engager, BiTE, BLINCYTObiobsab

Recently, Amgen announced the long-term efficacy of the company’s bispecific antibody Blincyto (blinatumomab) in the treatment of patients with acute lymphoblastic leukemia (ALL) at the European Hematology Association (EHA) conference. The medianRead More…

22Nov/18

Research and Development of Blinatumomab in B Cell Malignant Tumor

November 22, 2018Bispecific Antibody Clinic, Bispecific Antibody ResearchBispecific Antibody, Bispecific T Cell Engager, Blinatumomabbiobsab

Blinatumomab is a CD19/CD3 bispecific antibody that is the first bispecific T cell engager (BiTE) and the first CD19-specific antibody approved by the U.S. Food and Drug Administration (FDA). As an immunotherapyRead More…

02Oct/18

The World’s First-and-Only Bispecific T Cell Engager Immunotherapy Approved in Japan

October 2, 2018Bispecific Antibody Research, NewsBispecific T Cell Engager, Immunotherapybiobsab

Amgen, the United States biotechnology giant, recently announced that the Ministry of Health, Labor and Welfare (MHLW) has approved bispecific T cell engager immunotherapy Blincyto® (blinatumomab) for the treatment of relapsed orRead More…